 | Up a level |
Chung, Hyun Cheol and Kang, Yoon-Koo and Chen, Zhendong and Bai, Yuxian and Ishak, Wan Zamaniah Wan and Shim, Byoung Yong and Park, Young Lee and Koo, Dong-Hoe and Lu, Jianwei and Xu, Jianming and Chon, Hong Jae and Bai, Li-Yuan and Zeng, Shan and Yuan, Ying and Chen, Yen-Yang and Gu, Kangsheng and Zhong, Wen Yan and Kuang, Shu and Shih, Chie-Schin and Qin, Shu-Kui (2022) Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer, 128 (5). pp. 995-1003. ISSN 0008-543X, DOI https://doi.org/10.1002/cncr.34019.
Fnu, Noorulain and Kuan, Wai-Chee and Kong, Yek-Ching and Bustamam, Ros Suzanna and Wong, Li Ping and Subramaniam, ShriDevi and Ho, Gwo Fuang and Zaharah, Hafizah and Yip, Cheng-Har and Bhoo-Pathy, Nirmala (2022) Cancer-related costs, the resulting financial impact and coping strategies among cancer survivors living in a setting with a pluralistic health system: A qualitative study. ecancermedicalscience, 16. ISSN 1754-6605, DOI https://doi.org/10.3332/ecancer.2022.1449.
Rischin, Danny and Harrington, Kevin J. and Greil, Richard and Soulieres, Denis and Tahara, Makoto and de Castro Jr, Gilberto and Psyrri, Amanda and Brana, Irene and Neupane, Prakash and Bratland, Ase and Fuereder, Thorsten and Hughes, Brett G. M. and Mesia, Ricard and Ngamphaiboon, Nuttapong and Rordorf, Tamara and Ishak, Wan Zamaniah Wan and Hong, Ruey-Long and Mendoza, Rene Gonzalez and Jia, Liyi and Chirovsky, Diana and Norquist, Josephine and Jin, Fan and Burtness, Barbara (2022) Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology, 128. ISSN 1368-8375, DOI https://doi.org/10.1016/j.oraloncology.2022.105815.
